Jubilant Pharmova Complete Financial Statements
12 Years of Data
2026 - 2015
In FY2026, Jubilant Pharmova (JUBLPHARMA) reported revenue ₹2,296 Cr, net profit ₹119 Cr and EPS ₹7.55, with a net profit margin of 5.2% and ROE of 1.7%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Review JUBLPHARMA price earnings ratio to evaluate earnings-based valuation against sector peers.
Complete Financial Data Export
Profitability Ratios
Net Profit Margin
5.18%
2026 data
EBITDA Margin
14.46%
2026 data
Operating Margin
14.00%
2026 data
Return on Assets
0.77%
2026 data
Return on Equity
1.68%
2026 data
Balance Sheet Ratios
Current Ratio
0.70
2026 data
Equity Ratio
45.69%
2026 data
Asset Turnover
0.15
2026 data
JUBLPHARMA Revenue, Net Profit & EBITDA — Year-on-Year Growth
JUBLPHARMA YoY (Mar 2025 vs Mar 2026) — revenue +19.1%, net profit -21.2%, EBITDA -2.6%, expenses +23.8%. Explore JUBLPHARMA Benjamin Graham valuation to estimate fundamental worth using multiple valuation models.
Revenue Growth
+19.1%
Year-over-Year
Net Profit Growth
-21.2%
Year-over-Year
EBITDA Growth
-2.6%
Year-over-Year
Expense Growth
+23.8%
Year-over-Year
Assets Growth
+21.7%
Year-over-Year
Equity Growth
+13.7%
Year-over-Year
Operating Cash Flow Growth
+10.4%
Year-over-Year
Investing Cash Flow Growth
+186.1%
Year-over-Year
Financing Cash Flow Growth
-235.6%
Year-over-Year
JUBLPHARMA Income Statement — Revenue, EBITDA & Net Profit
Jubilant Pharmova revenue ₹2,296 Cr, EBITDA ₹332 Cr, net profit ₹119 Cr, EPS ₹7.55 (2026) — net profit margin 5.2%. For live price, earnings ratios and company overview, see Jubilant Pharmova screener.
Periods
₹ Crores
| Particulars | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Dec 2023 | Sept 2022 | Mar 2022 | Jun 2022 | Dec 2022 | Sept 2021 | Mar 2021 | Jun 2021 | Dec 2021 | Sept 2020 | Mar 2020 | Jun 2020 | Dec 2020 | Sept 2019 | Mar 2019 | Jun 2019 | Dec 2019 | Sept 2018 | Mar 2018 | Jun 2018 | Dec 2018 | Sept 2017 | Mar 2017 | Jun 2017 | Dec 2017 | Sept 2016 | Mar 2016 | Jun 2016 | Dec 2016 | Sept 2015 | Mar 2015 | Jun 2015 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,296 | 1,968 | 1,928 | 1,891 | 2,137 | 1,764 | 1,764 | 2,130 | 1,823 | 1,686 | 1,682 | 1,575 | 1,714 | 1,598 | 1,513 | 1,452 | 1,543 | 1,638 | 1,614 | 1,617 | 1,304 | 1,631 | 1,563 | 1,175 | 1,838 | 2,249 | 2,346 | 2,163 | 1,544 | 2,249 | 2,247 | 2,056 | 2,382 | 1,628 | 1,576 | 1,545 | 2,045 | 1,365 | 1,466 | 1,405 | 1,444 | 1,439 | 1,529 | 1,430 | 1,327 |
| Expenses | 1,964 | 1,631 | 1,587 | 1,611 | 1,873 | 1,477 | 1,656 | 1,480 | 1,554 | 1,439 | 1,459 | 1,419 | 1,459 | 1,440 | 1,280 | 1,259 | 1,408 | 1,319 | 1,216 | 1,269 | 1,116 | 1,242 | 1,131 | 977 | 1,293 | 1,798 | 2,262 | 1,747 | 1,141 | 1,828 | 1,794 | 1,663 | 1,899 | 1,336 | 1,293 | 1,219 | 1,651 | 1,045 | 1,192 | 1,051 | 1,126 | 1,129 | 1,323 | 1,121 | 1,061 |
| EBITDA | 332 | 337 | 341 | 280 | 264 | 287 | 108 | 650 | 269 | 247 | 223 | 156 | 255 | 158 | 233 | 192 | 134 | 319 | 398 | 348 | 187 | 389 | 432 | 199 | 546 | 451 | 83 | 415 | 403 | 422 | 453 | 393 | 483 | 293 | 283 | 327 | 394 | 319 | 274 | 354 | 318 | 310 | 206 | 309 | 266 |
| Operating Profit Margin % | 14.00% | 17.00% | 17.00% | 14.00% | 12.00% | 15.00% | 5.00% | 14.00% | 14.00% | 14.00% | 12.00% | 9.00% | 12.00% | 9.00% | 15.00% | 13.00% | 8.00% | 19.00% | 22.00% | 21.00% | 14.00% | 20.00% | 24.00% | 13.00% | 26.00% | 20.00% | 4.00% | 19.00% | 24.00% | 19.00% | 19.00% | 19.00% | 19.00% | 18.00% | 17.00% | 21.00% | 19.00% | 23.00% | 19.00% | 25.00% | 22.00% | 21.00% | 13.00% | 21.00% | 20.00% |
| Depreciation | 117 | 105 | 95 | 98 | 121 | 91 | 101 | 91 | 91 | 97 | 271 | 90 | 95 | 94 | 101 | 95 | 94 | 100 | 86 | 88 | 93 | 85 | 98 | 82 | 96 | 117 | 95 | 103 | 84 | 90 | 182 | 88 | 98 | 79 | 75 | 73 | 82 | 72 | 127 | 72 | 73 | 75 | 66 | 70 | 75 |
| Interest | 57 | 50 | 53 | 49 | 56 | 61 | 73 | 71 | 56 | 66 | 56 | 62 | 71 | 42 | 40 | 40 | 51 | 35 | 43 | 35 | 37 | 47 | 47 | 48 | 46 | 72 | 62 | 73 | 49 | 54 | 73 | 51 | 53 | 66 | 80 | 69 | 77 | 80 | 99 | 83 | 98 | 92 | 85 | 91 | 89 |
| Profit Before Tax | 176 | 190 | 206 | 154 | 93 | 144 | -54 | 500 | 131 | 98 | -86 | 25 | 101 | 36 | 106 | 69 | 9 | 208 | 297 | 247 | 70 | 299 | 358 | 106 | 431 | 292 | -40 | 269 | 294 | 302 | 227 | 286 | 356 | 168 | 160 | 203 | 261 | 193 | 69 | 218 | 166 | 161 | 68 | 168 | 145 |
| Tax | 57 | 70 | 55 | 52 | 38 | 42 | 8 | 18 | 30 | 36 | 14 | 19 | 35 | 32 | 47 | 22 | 25 | 65 | 83 | 86 | 19 | 75 | 98 | 18 | 121 | 43 | 61 | 84 | 90 | 92 | 74 | 86 | 88 | 43 | 11 | 60 | 48 | 50 | 58 | 54 | 48 | 36 | 25 | 37 | 24 |
| Net Profit | 119 | 120 | 151 | 103 | 56 | 103 | -62 | 482 | 101 | 62 | -101 | 6 | 66 | 5 | 59 | 47 | -16 | 143 | 214 | 161 | 51 | 224 | 261 | 88 | 310 | 249 | -101 | 185 | 203 | 210 | 152 | 200 | 268 | 126 | 149 | 144 | 213 | 144 | 11 | 164 | 118 | 125 | 43 | 130 | 122 |
| Earnings Per Share (₹) | 7.55 | 7.59 | 9.71 | 6.49 | 3.52 | 6.47 | -3.69 | 30.44 | 6.37 | 3.94 | -6.15 | 0.40 | 4.22 | 0.34 | 3.74 | 2.96 | -0.98 | 8.97 | 13.43 | 10.09 | 3.20 | 14.06 | 16.35 | 5.53 | 19.46 | 15.66 | -6.38 | 11.61 | 12.77 | 13.50 | 9.94 | 13.00 | 16.74 | 8.23 | 9.63 | 9.44 | 13.64 | 9.29 | 0.72 | 10.39 | 7.66 | 8.11 | 2.68 | 8.28 | 7.90 |
JUBLPHARMA Balance Sheet — Assets, Liabilities & Shareholders' Equity
JUBLPHARMA total assets ₹15,523 Cr, total equity ₹7,093 Cr, total liabilities ₹ Cr (2026) — ROE 1.7%.
Years
Annual Data
₹ Crores
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| Total Assets | 15,523 | 12,756 | 11,549 | 11,157 | 9,991 | 8,918 | 12,522 | 11,469 | 9,618 | 9,041 | 8,824 | 8,619 |
| Current Assets | 4,109 | 3,577 | 3,876 | 3,762 | 3,509 | 2,953 | 5,038 | 4,585 | 3,190 | 2,948 | 2,875 | 2,715 |
| Fixed Assets | 8,180 | 5,176 | 5,091 | 5,183 | 4,871 | 4,609 | 6,340 | 5,648 | 5,401 | 5,107 | 5,104 | 4,911 |
| Capital Work in Progress | 2,962 | 3,630 | 2,103 | 1,562 | 1,090 | 897 | 768 | 901 | 671 | 684 | 611 | 597 |
| Investments | 1,232 | 44 | 42 | 256 | 239 | 241 | 69 | 115 | 124 | 103 | 85 | 0 |
| Other Assets | 0 | 3,907 | 4,312 | 4,156 | 3,792 | 3,171 | 5,344 | 4,804 | 3,423 | 3,147 | 3,023 | 3,111 |
| LIABILITIES | ||||||||||||
| Total Liabilities | ||||||||||||
| Current Liabilities | 5,888 | 4,353 | 4,238 | 3,993 | 3,083 | 3,128 | 4,299 | 4,570 | 3,578 | 3,968 | 3,432 | 4,036 |
| Non-Current Liabilities | ||||||||||||
| SHAREHOLDERS' EQUITY | ||||||||||||
| Total Equity | 7,093 | 6,239 | 5,421 | 5,392 | 5,316 | 4,742 | 5,604 | 4,809 | 4,035 | 3,389 | 2,928 | 2,454 |
| Share Capital | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves & Surplus | 7,077 | 6,239 | 5,418 | 5,383 | 5,303 | 4,726 | 5,588 | 4,793 | 4,071 | 3,421 | 2,951 | 2,438 |
JUBLPHARMA Cash Flow Statement — Operating, Investing & Financing
Jubilant Pharmova operating cash flow ₹1,072 Cr, investing ₹513 Cr, financing ₹-1,453 Cr, net cash flow ₹132 Cr (2025).
Periods
₹ Crores
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1,072 | 971 | 661 | 838 | 1,784 | 1,543 | 1,122 | 1,303 | 1,269 | 1,099 | 783 |
| Investing Activities | 513 | -596 | -474 | -323 | -727 | -267 | -1,018 | -614 | -465 | -309 | -362 |
| Financing Activities | -1,453 | -433 | -157 | -33 | -1,709 | -1,050 | 657 | -901 | -686 | -843 | -503 |
| Net Cash Flow | 132 | -58 | 30 | 482 | -652 | 225 | 761 | -212 | 117 | -52 | -82 |